NASDAQ:EVAX

Evaxion Biotech A/S (EVAX) Stock Forecast, Price & News

$0.79

+0.05 (+6.76%)

(As of 09/26/2023 ET)

Compare

Today's Range: $0.69
▼
$0.79
50-Day Range: $0.48
▼
$1.27
52-Week Range: $0.47
▼
$3.10

Volume: 166,640 shs
Average Volume: 254,918 shs
Market Capitalization: $21.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Evaxion Biotech A/S MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,039.2% Upside
$9.00 Price Target
Short Interest: Healthy
0.63% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.85
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

260th out of 963 stocks

Biological Products, Except Diagnostic Industry

37th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Evaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Evaxion Biotech A/S has a forecasted upside of 1,039.2% from its current price of $0.79.
Amount of Analyst Coverage
Evaxion Biotech A/S has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.63% of the outstanding shares of Evaxion Biotech A/S have been sold short.
Short Interest Ratio / Days to Cover
Evaxion Biotech A/S has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Evaxion Biotech A/S has recently decreased by 23.78%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Evaxion Biotech A/S does not currently pay a dividend.
Dividend Growth
Evaxion Biotech A/S does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EVAX.

3.2

News and Social Media Coverage

News Sentiment
Evaxion Biotech A/S has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Evaxion Biotech A/S this week, compared to 1 article on an average week.
Search Interest
2 people have searched for EVAX on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Evaxion Biotech A/S to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.58% of the stock of Evaxion Biotech A/S is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Evaxion Biotech A/S is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evaxion Biotech A/S is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Evaxion Biotech A/S has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Evaxion Biotech A/S (NASDAQ:EVAX) Stock

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

EVAX Price History

30 days | 90 days | 365 days | Advanced Chart

EVAX Stock News Headlines

September 26, 2023 | americanbankingnews.com

Evaxion Biotech A/S (NASDAQ:EVAX) Stock Price Down 3.7%

September 21, 2023 | finance.yahoo.com

Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 20, 2023 | finanznachrichten.de

Evaxion Biotech: Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea

September 20, 2023 | finance.yahoo.com

Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea

September 18, 2023 | finance.yahoo.com

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

August 30, 2023 | bloomberg.com

Novo Buys Embark Biotech to Find New Avenues for Weight Loss

August 29, 2023 | finanznachrichten.de

Evaxion Biotech: Evaxion announces Executive Management Changes to strengthen the AI-strategy

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

August 29, 2023 | finance.yahoo.com

Evaxion announces Executive Management Changes to strengthen the AI-strategy

August 24, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Rising, Backed by Mostly Firmer Markets

August 23, 2023 | finance.yahoo.com

Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript

August 23, 2023 | finance.yahoo.com

Q2 2023 Evaxion Biotech A/S Earnings Call

August 18, 2023 | finanznachrichten.de

Evaxion Biotech: Evaxion Announces Business Update and Second Quarter 2023 Financial Results

August 18, 2023 | finance.yahoo.com

Evaxion Announces Business Update and Second Quarter 2023 Financial Results

August 3, 2023 | msn.com

Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst

August 1, 2023 | msn.com

Evaxion gets $20M financing from Negma

August 1, 2023 | finance.yahoo.com

Evaxion announces financing commitments totaling up to USD 20 million with Negma Group

July 31, 2023 | finance.yahoo.com

Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus

July 10, 2023 | seekingalpha.com

Iovance Biotherapeutics: More Than A One-Shot Wonder

July 8, 2023 | axios.com

Thermo Fisher to buy Audax’s CorEvitas for $913M

June 8, 2023 | foxnews.com

Cancer drug firms soar as positive clinical trial data ignites investor excitement

June 5, 2023 | marketwatch.com

ADRs End Mostly Lower, BiondVax, Evaxion Biotech Trade Actively

June 5, 2023 | news.yahoo.com

Cancer drugmakers rise as industry meet fuels investor interest

June 5, 2023 | marketwatch.com

Evaxion Biotech Shares Rise 38% After Positive EVX-01 Phase 1 Trial Data

June 5, 2023 | finance.yahoo.com

Why Are Evaxion Biotech Shares Trading Higher Today

June 3, 2023 | finance.yahoo.com

Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

See More Headlines

Receive EVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.

EVAX Company Calendar

Last Earnings: 8/22/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EVAX
CUSIP: N/A
CIK: 1828253
Web: www.evaxion-biotech.com
Phone: 45-5353-1850
Fax: N/A
Employees: 63
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +1,039.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -452.78%
Return on Assets: -126.54%

Debt

Debt-to-Equity Ratio: 3.95
Current Ratio: 2.81
Quick Ratio: 2.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.35 per share
Price / Book: 2.26

Miscellaneous

Outstanding Shares: 27,650,000
Free Float: 16,138,000
Market Cap: $21.84 million
Optionable: Not Optionable
Beta: 0.53

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Niels Iversen Moeller M.D. (Age 44)
Co-Founder, VP of Bus. & Director
Comp: $120k

Mr. Andreas Holm Mattsson (Age 47)
Co-Founder and Chief AI & Culture Officer
Comp: $319k

Mr. Jesper Nyegaard Nissen (Age 53)
CFO & COO
Comp: $346.97k

Dr. Birgitte Rono Ph.D. (Age 47)
Chief Scientific Officer
Comp: $336k

Mr. Christian Kanstrup (Age 51)
Chief Exec. Officer

Dr. Jürgen Langhärig EMBA
Ph.D., Head of Bus. Devel. & Member of Advisory Board

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

EVAX Stock - Frequently Asked Questions

Should I buy or sell Evaxion Biotech A/S stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EVAX shares.
View EVAX analyst ratings or view top-rated stocks.
What is Evaxion Biotech A/S's stock price forecast for 2023?: 2 brokers have issued 1-year price objectives for Evaxion Biotech A/S's stock. Their EVAX share price forecasts range from $7.00 to $11.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,039.2% from the stock's current price.
View analysts price targets for EVAX or view top-rated stocks among Wall Street analysts.
How have EVAX shares performed in 2023?: Evaxion Biotech A/S's stock was trading at $1.7750 at the beginning of the year. Since then, EVAX stock has decreased by 55.5% and is now trading at $0.79.
View the best growth stocks for 2023 here.
When is Evaxion Biotech A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our EVAX earnings forecast.
How were Evaxion Biotech A/S's earnings last quarter?: Evaxion Biotech A/S (NASDAQ:EVAX) announced its quarterly earnings results on Tuesday, August, 22nd. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01.
When did Evaxion Biotech A/S IPO?: (EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at a price of $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Evaxion Biotech A/S's stock symbol?: Evaxion Biotech A/S trades on the NASDAQ under the ticker symbol "EVAX."
Who are Evaxion Biotech A/S's major shareholders?: Evaxion Biotech A/S's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (0.11%) and Citadel Advisors LLC (0.00%).
How do I buy shares of Evaxion Biotech A/S?: Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Evaxion Biotech A/S's stock price today?: One share of EVAX stock can currently be purchased for approximately $0.79.
How much money does Evaxion Biotech A/S make?: Evaxion Biotech A/S (NASDAQ:EVAX) has a market capitalization of $21.84 million. The company earns $-23,170,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.
How can I contact Evaxion Biotech A/S?: Evaxion Biotech A/S's mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The official website for the company is www.evaxion-biotech.com. The company can be reached via phone at 45-5353-1850 or via email at info@evaxion-biotech.com.

This page (NASDAQ:EVAX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial